AU Patent

AU2023234590A1 — Treatment of cutaneous neurofibromas with mirdametinib

Assigned to SpringWorks Therapeutics Inc · Expires 2024-10-03 · 2y expired

What this patent protects

The present disclosure relates to methods for treating cutaneous neurofibromas (cNF) comprising administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.

USPTO Abstract

The present disclosure relates to methods for treating cutaneous neurofibromas (cNF) comprising administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2023234590A1
Jurisdiction
AU
Classification
—
Expires
2024-10-03
Drug substance claim
No
Drug product claim
No
Assignee
SpringWorks Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.